Start Codon

Anne Horgan blends McKinsey strategy consulting with synthetic organic and medicinal chemistry (PhD Cambridge; Max Planck postdoc; GSK), formalizing university-commercial links via a Clare Hall fellowship and BioIndustry Association board

Ian Lane focuses on applying AI to scientific discovery in semiconductors and quantum technologies, serves as CogX’s Los Angeles Ambassador, and takes hands-on board roles like Seldon.

Michael Anstey pairs a DPhil in Zoology with co-founding an early-stage biotech targeting protein–protein interactions, backed Bicycle Therapeutics and Nuclera, and co-founded Innovate Cambridge to boost Greater Cambridge's innovation ecosystem.

Philip Winter is a startup founder and investor who co-founded the hardware company Nebia, which was acquired by Brondell nine years later. He more recently led Supplant, a Cambridge biotech spin-out, serving as interim CEO through its 2025 acquisition. He is a general partner at Latitude Fund, previously worked as a deep tech investor at Creator Fund, and holds an MBA from the University of Cambridge and a B.A. from the University of Pennsylvania.

Rob Sprawson is a Partner and CFO at Cambridge Innovation Capital. He has over 30 years of experience in strategic financial advisory services across the pharmaceutical, biotech, technology, and technology consulting sectors, working with boards and shareholders.

Edward Inns focuses on deep tech, investing in quantum computing infrastructure and error‑correction companies like Riverlane rather than hardware, and explains complex quantum concepts to investor audiences across media.

Rowan Chapman is co-founder at BEVC and serves as an entrepreneur, investor, and board member. With experience spanning startups to Fortune 50 companies, Chapman has executed numerous transactions in therapeutics, digital health, research tools, diagnostics, vaccines, and medical devices, and maintains expertise in team building, business planning, equity investing, M&A, and LP relations. Chapman holds NACD Directorship Certification.

Robert Tansley is a trained surgeon-turned-investor who leverages clinical experience, backing major medtechs like CMR Surgical, serving as CMO and translating Cambridge academic research into scalable life sciences companies.

A pharma R&D leader, biotech entrepreneur and antibody engineer. He co-founded and was CSO of Domantis (sold to GSK in 2007 for $454m), later served as SVP and Head of Worldwide Business Development at GSK, and chaired Stevenage Bioscience Catalyst and Apollo Therapeutics.

Physician-scientist trained at Cambridge and Oxford specializing in neurology, formerly at AstraZeneca Neuroscience and an EIR at several life-science funds. Focus area: biotech.

Recognized among GrowthCap's Top Women Leaders in Growth Investing of 2026.

Ilana Wisby is a quantum physicist and deep tech entrepreneur who was the founding CEO of Oxford Quantum Circuits (OQC), which she built from a single 2018 patent into a UK quantum company with a 135+ person team across the UK, Japan and Spain and over £100m raised. She has advised UK governments and served on bodies including the UK Business Innovation Forum Council and the World Economic Forum's Global Future Council on Quantum Computing. She holds a PhD in experimental quantum physics from Royal Holloway and the National Physical Laboratory.

William Tunstall-Pedoe founded a company whose technology (Evi) was acquired by Amazon and became part of Alexa; he held a senior role in the team that defined, built and launched the Amazon Echo. He now works as an angel investor and is a fellow of the Creative Destruction Lab, a Toronto-based AI startup incubator. He holds a first class honours degree in Computer Science from Churchill College, Cambridge.